Discontinued — last reported Q4 '22
Johnson & Johnson Consumer Health Business — Restructuring (Note 20) remained flat by 0.0% to $25.00M in Q4 2022 compared to the prior quarter.
An increase reflects active efforts to improve efficiency, which may lead to short-term margin pressure but potential long-term cost savings. A decrease suggests that the segment has reached a period of operational stability.
This metric tracks the costs associated with organizational changes, facility consolidations, and workforce adjustments...
Similar to 'restructuring charges' or 'transformation costs' reported by diversified consumer goods and healthcare companies to highlight non-recurring operational improvements.
jnj_segment_consumer_health_business_restructuring_note_20| FY'22 | |
|---|---|
| Value | $100.00M |